Arrivent Biopharma, Inc. balance sheet AVBP

Annual Quarterly

As of Jun 30, 2026, Arrivent Biopharma, Inc. had total assets of $394.7 million and total liabilities of $27.9 million. Total assets were up 46.5% from a year earlier. Stockholders' equity was $366.8 million. It held $373.1 million in cash and investments against $351,000 of total debt, net cash of $372.8 million. The current ratio, current assets divided by current liabilities, was 14.16.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Assets
Cash	155 +37.2%	62 +24.5%	46 -38.7%	113 -60.2%	113 -62.2%	50 -84.3%	74	283
Short-term investments	218 +77.7%	264 +109.4%	267 +84.9%	188	123	126	145	—
Long-term investments	—	—	—	5	19	29	48	—
Cash and investments	373 +46.6%	326 +58.8%	313 +42.9%	305 +8.0%	254 -14.8%	205 -35.3%	267	283
Total current assets	394 +57.6%	349 +87.7%	333 +46.7%	321 +9.9%	250 -18.9%	186 -43.3%	227	292
Total assets	395 +46.5%	349 +62.1%	333 +21.2%	327 +11.6%	270 -12.7%	215 -34.3%	275	293
Liabilities and equity
Accounts payable	2 -45.4%	9 +100.0%	6 +56.9%	6 +27.7%	4 +6.5%	4 +6.5%	4	5
Total current liabilities	28 +41.8%	25 +93.0%	26 +50.2%	22 +42.2%	20 +62.3%	13 +29.8%	17	15
Total liabilities	28 +42.0%	25 +95.4%	26 +50.1%	22 +41.7%	20 +61.0%	13 +28.1%	17	15
Stockholders' equity	367 +46.8%	324 +60.0%	307 +19.2%	305 +9.9%	250 -15.8%	203 -36.3%	258	277
Debt
Lease liabilities	0 +258.2%	0 +203.6%	0 -92.0%	0 -73.7%	0 -60.8%	0 -51.6%	0	0
Total debt	0 +258.2%	0 +203.6%	0 -92.0%	0 -73.7%	0 -60.8%	0 -51.6%	0	0
Net cash	373 +46.5%	326 +58.7%	313 +43.0%	305 +8.0%	254 -14.8%	205 -35.2%	266	283
Ratios
Current ratio	14.16x	13.95x	12.83x	14.90x	12.74x	14.34x	13.14x	19.28x
Debt to equity	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x
Return on equity	-44.63%	-44.83%	-54.13%	-49.64%	-54.82%	-62.93%	-31.24%	—
Return on assets	-41.48%	-41.58%	-49.92%	-46.36%	-50.83%	-59.15%	-29.27%	—
Book value per share	7.59	7.15	7.24	7.47	6.66	5.95	7.64	8.24

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: AVBP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Newtown Square, PA
SEC filer status: , Emerging growth company
SEC CIK: 1868279

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.